| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f815b36b41237d931354b4833bf8c9df |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4458 |
| filingDate |
1998-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c65345c3fcc082562867140a41d2737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed173cd6020aec1410066e07ff87b1f5 |
| publicationDate |
2001-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SI-20360-A |
| titleOfInvention |
Means and methods for treating disorders related to imbalance and hyperactive disorders related to imbalance with methylphenidate |
| abstract |
The invention relates to methods of treating imbalance disorders (ADD) and hyperactivity disorder imbalances (ADHD) as well as agents for the topical use of methylphenidate in a pharmaceutically variable flexible end system, where methylphenidate is present in an amount dispensed through the patient skin or mucous membrane is sufficient to achieve essentially zero-order kinetics over a period of at least 10 hours. |
| priorityDate |
1997-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |